ImmunoGen Inc. (IMGN)
NASDAQ: IMGN
· Real-Time Price · USD
31.23
0.00 (0.00%)
At close: Feb 09, 2024, 8:58 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 8.73B |
| Revenue (ttm) | 287.61M |
| Net Income (ttm) | -73.07M |
| EPS (ttm) | -0.28 |
| PE Ratio (ttm) | -111.55357142857143 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 19,311,442 |
| Avg. Volume (20D) | 8,287,745 |
| Open | 31.24 |
| Previous Close | 31.23 |
| Day's Range | 31.22 - 31.25 |
| 52-Week Range | 3.61 - 31.25 |
| Beta | 1.17 |
About IMGN
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 1989
Employees 277
Stock Exchange NASDAQ
Ticker Symbol IMGN
Website https://www.immunogen.com